Xenon Pharmaceuticals Inc
XENE
Market Cap$3.24B
Close$
$2.06
95.2% downside
Current Fair Value
95.2% downsideOvervalued by 95.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.24 Billion |
|---|---|
| Enterprise Value | $2.72 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.5 |
| Beta | 0.65 |
| Outstanding Shares | 75,463,489 |
| Avg 30 Day Volume | 350,616 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -19.78 |
|---|---|
| PEG | -37.81 |
| Price to Sales | - |
| Price to Book Ratio | 5.37 |
| Enterprise Value to Revenue | 20582.09 |
| Enterprise Value to EBIT | -14.6 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone